LSLarisa Evgenievna Sivordova

Larisa Evgenievna Sivordova

*This is an algorithmically generated author record based on publicly available information.

Larisa Evgenievna Sivordova has a total of 81 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • TNF-associated apoptosis-inducing ligand in patients with rheumatic diseases

    by E. V. Papichev, L. E. Sivordova, Yu. R. Akhverdyan, Yu. V. Polyakova, N. V. Aleksandrova, B. V. Zavodovsky

    Impaired immune tolerance and dysregulation of programmed cell death pathways are central mechanisms inpathogenesis of autoimmunerheumaticdiseases. Tumor necrosis factor (TNF)-relatedapoptosisinducing ligand (TRAIL) is an important immunoregulatory molecule involved in elimination of autoreactive lymphocytes and modulation of innate and adaptive immune responses. In addition to its proapoptotic activity, this ligand may activate non-apoptotic signaling pathways associated with cytokine production, cell survival, and chronic inflammation. However, its contribution to immune dysregulation in rheumatic diseases remains poorly studied. The objective of the present work was to evaluate serum levels of TRAIL in patients with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and ankylosing spondylitis (AS), and to investigate its associations with clinical and immunological disease characteristics. This pilot study included 73 participants: 18 patients with RA, 29 with SLE, 16 with AS, and 9 healthy controls. Serum levels of TRAIL were measured by ELISA technique. Immunological testing included determination of rheumatoid factor, antibodies to cyclic citrullinated peptides, antibodies to double-stranded DNA, and serum complement components. Statistical evaluation included comparative, correlation, and receiver operating characteristic curve analyses. Patients with RA exhibited significantly elevated serum levels of TRAIL compared with healthy controls and patients with SLE or AS. A trend toward higher concentrations was observed in antibody-positive rheumatoid arthritis, suggesting a relationship between this mediator and autoimmune activation. In SLE, increased ligand levels were associated with joint involvement, potentially reflecting enhanced type I interferon-driven immune activation. ROC analysis demonstrated high diagnostic performance of the biomarker for identifying RA. Elevated serum levels of TRAIL are associated with RA and may reflect disturbances in apoptosis-mediated immune regulation and persistence of autoimmune inflammation. These findings support the involvement of this mediator in immunopathogenesis of rheumatic diseases and highlight its potential utility as a component of immunological biomarker panels for rheumatoid arthritis.

  • Open Access

    Clinical and pathogenetic significance of monocyte chemotactic protein-1 in rheumatoid arthritis: A literature review

    by L. E. Sivordova, E. V. Papichev, Yu. V. Polyakova, Yu. R. Akhverdyan, N. A. Aleksandrova, B. V. Zavodovsky, Л. Е. Сивордова, Е. В. Папичев, Ю. В. Полякова, Ю. Р. Ахвердян, et al.

    Monocyte chemotactic protein-1 (MCP-1), also known as C-C motif chemokine ligand 2 (CCL2), plays a key role in regulating inflammation in various pathologies. It is directly or indirectly implicated in the pathogenesis of oncologic and pulmonary diseases, neuroinflammatory, cardiovascular, and skin diseases. Its role as a biomarker of disease severity has been proven. The role of this chemokine in the pathogenesis of immune-mediated inflammatory rheumatic diseases remains insufficiently studied and is of considerable scientific interest. The aim of this literature review was to analyze scientific data on the pathogenetic role of MCP-1 in rheumatoid arthritis (RA) and the prospects for its use in clinical practice. A search for scientific publications was performed in the electronic databases PubMed, Google Scholar, and eLIBRARY.RU, published in Russian and English before February 2026. This review of the scientific literature clarified the role of MCP-1 in the pathogenesis of RA and highlighted one of the most pressing areas of scientific research: the development of new drugs (antagonists of the receptor of this chemokine, CCR2). MCP-1 has been shown to play a key role in enhancing the inflammatory cascade and is closely associated with chronic, uncontrolled inflammation. MCP-1 exerts its biological effects on migration, infiltration, and differentiation of immune cells by binding to its receptor, CCR2. The MCP-1 (CCL2)/CCR2 axis is a central inflammatory mechanism that attracts monocytes to the site of inflammation. Currently, proposed CCR2 antagonist drugs are not sufficiently effective, and extrapolation of experimental results in animal models does not justify clinical trials. Nevertheless, the development of new CCR2 antagonists and/or their combination with other immunomodulators may be a promising strategy for improving the effectiveness of RA treatment.

  • Open Access

    Laboratory assessment of bone metabolism parameters by determining serum C-terminal type I collagen telopeptides in patients with rheumatoid arthritis

    by Yu. R. Akhverdyan, Б. В. Заводовский, E. V. Papichev, Yu. V. Polyakova, L. E. Sivordova, Ю. Р. Ахвердян, Ю. В. Полякова

    The aim of the study was to investigate the relationship between the serum level of C-terminal telopeptides of type I collagen and clinical and laboratory features of rheumatoid arthritis in elderly female patients. We observed 87 patients with a reliable diagnosis of RA. The average age of the patients was 67.4±6.9 (61.7-73.4) years. The duration of RA ranged from 0.2 to 33 years (9 [4-16]). The average level of β-Cross Laps in patients with RA was 0.684 [0.40-0.78] ng/ml, an increase in the upper limit of the norm was observed in 28 (32.2%) patients. No significant relationship was found between the level of β-Cross Laps and age, as well as height, weight and BMI of the patients. A relationship was found between the concentration of β-Cross Laps and disease activity (K-W χ2=3.318, p=0.042), radiographic stage (K-W χ2=2.960, p=0.036), functional class (K-W χ2=3.639, p=0.030) and CRP level (ρ=3.1907; p= 0.037).

  • Characteristics of Patients with Secondary Osteoporotic Fractures: Risk Factors, Diagnosis, and Treatment According to PROMETHEUS Registry Data

    by Ksenia Yu. Belova, Maria I. Fominykh, Mikhail V. Belov, Elena N. Gladkova, Khatia G. Gordzheladze, Ekaterina N. Dudinskaya, Ludmila P. Evstigneeva, Olga M. Lesnyak, Evgeniya L. Matveychenko, Julia V. Polyakova, et al.

    BACKGROUND: Individuals who have suffered fragility fractures, deserve special attention. Diagnosis and treatment of such patients remain unsatisfactory. To address this issue, in 2012, the Russian Association for Osteoporosis initiated the PROMETHEUS project (abbreviation of Russian expression ‘creation of services for secondary fractures prevention in patients with osteoporosis’) aimed to improve the prevention of secondary fractures. AIM: To analyze the incidence rate of previous osteoporotic fractures in patients aged 50 years and older enrolled in the Secondary Fracture Prevention Service (SFPS) evaluate their risk factors, identify if these patients had been previously diagnosed with osteoporosis and received anti-osteoporotic treatment. METHODS: A continuous, cross-sectional, multicenter, observational case-control study was conducted. The study group consisted of patients with a history of any fragility fractures (apart from the ‘index’ fracture). The control group included patients who did not report any previous fractures. Risk factors, diagnosis, and anti-osteoporotic therapy were analyzed. RESULTS: During the study period, 991 patients were enrolled in the registry. Of these, 443 (44.7%) had a history of fragility fractures. The number of previous fractures per patient ranged from 1 to 11, with 273 (61.62%) patients having one previous fracture and 103 (23.25%) having two. Risk factors for fracture include disability (OR 1.67, 95% CI 1.22–2.30), thyrotoxicosis (OR 2.90, 95% CI 1.12–7.47), and chronic obstructive pulmonary disease (OR 2.81, 95% CI 1.00–7.95). CONCLUSION: Almost half of the patients included in SFPS had a history of previous fragility fractures. However, the frequency of diagnosing osteoporosis after the previous fracture and use of anti-osteoporotic drugs were quite low, which necessitates further improvements of medical care for elderly patients with osteoporotic fractures, as well as the wide introduction of SFPS, its integration in the primary care setting, and inclusion in educational programs for traumatologists and primary care physicians.

  • Open Access

    The value of fibroblast growth factor 21 in health and pathology

    by Yu. R. Akhverdyan, E. V. Papichev, Б. В. Заводовский, Yu. V. Polyakova, L. E. Seewordova, E. S. Rozhkova, Ю. Р. Ахвердян, Ю. В. Полякова

    The article presents current ideas about the role of fibroblast growth factor 21 (FGF21) in the regulation of carbohydrate and lipid metabolism, as well as its contribution to the development of systemic inflammation in rheumatoid arthritis, both in laboratory animals and in humans. The classification of the fibroblast growth factor family, regulation of expression and receptor apparatus is considered. Positive effects of FGF21 have been noted in the form of normalization of carbohydrate and lipid metabolism, body weight; drugs analogues of FGF21 have proven themselves well as a therapeutic agent for the treatment of metabolic complications such as diabetes and fatty liver disease. At the same time, data are provided on the connection between elevated levels of FGF21 in blood serum and a number of pathological conditions, such as type 2 diabetes mellitus, coronary heart disease, obesity, non-alcoholic fatty liver disease, and end-stage renal failure. The facts about the controversial role of FGF21 against the background of systemic inflammation in patients with rheumatoid arthritis (RA) are reviewed. On the one hand, FGF21 may have a protective effect in patients with RA; on the other hand, serum FGF21 can be considered as a predictor of future decline in functional status and a potential marker for the progression of systemic inflammation in patients with RA. The prospects for using FGF21 for therapeutic purposes are assessed.


  • Open Access

    Proinflammatory cytokines and the risk of osteoporotic fractures in postmenopausal breast cancer patients

    by Ninel V. Aleksandrova, Larisa E. Sivordova, Elizaveta R. Kurchina, Yaroslav D. Ershov, Andrey N. Krasilnikov, Yulia V. Polyakova, Полякова Юлия Васильевна

    Despite the increased risk of bone fractures in patients with malignant neoplasms (MN), especially breast cancer (BC), bone health assessment and preventive treatment of osteoporosis (OP) still remain understudied. The aim of our work was to investigate the significance of systemic inflammatory markers in relation to severity of osteoporotic changes, and to evaluate their association with the estimated 10-year risk of low-energy fractures determined by FRAX in postmenopausal patients with breast cancer. Patients and methods: The study included 85 postmenopausal women with different malignancies, including 40 BC patients. All patients with BC underwent dual-energy X-ray absorptiometry, the 10-year probability of fracture was assessed by FRAX. IL-1β, IL-6, and TNFα were measured by quantitative enzyme-linked immunosorbent assay. The mean time since diagnosis of MN until referral for osteoporosis (OP) was 3 (2.0-4.0) years. In patients with MN, OP was diagnosed in 51.2% of cases, and osteopenia – in 37.2%. In the group of BC patients, osteopenia was documented in 16 patients, OP, in 19 cases. Adjuvant chemotherapy was performed in 42.5% of cases among breast cancer patients, and adjuvant hormonal therapy was performed in 87.5% of cases (different postmenopausal hormone therapies were used). When comparing the cytokine levels in BC subgroups with presence (47.5%) or absence of OP, we have found that IL-1β was higher in patients with OP as compared to both normal persons and osteopenic patients (p = 0.027 and p = 0.029, respectively); IL-6 was higher only in patients with OP compared to normal subjects (p = 0.011); TNFα in OP and osteopenia exceeded those values in OP-free cases (p = 0.001 and p = 0.039, respectively). TNFα levels correlated with the risk score for large osteoporotic fractures (FRAX:MOF) (rS = 0.33, p = 0.036) and IL-6 (rS = 0.55). A higher 10-year risk of vertebral fractures (p = 0.003) was observed in the group of BC patients with ‘high’ ( median) TNFα levels. In summary, proinflammatory cytokines seem to be involved in bone resorption processes. Postmenopausal BC patients have an increased estimated 10-year risk of low-energy spine fractures associated with high TNFα levels.

  • Open Access

    PRO-INFLAMMATORY CYTOKINES AND THE RISK OF OSTEOPOROTIC FRACTURES IN POSTMENOPAUSAL BREAST CANCER PATIENTS

    by Nynel V. Aleksandrova, Larisa E. Sivordova, Elizaveta R. Kurchina, Yaroslav D. Ershov, Andrey N. Krasilnikov, Julia V. Polyakova, Полякова Юлия Васильевна

    Despite the increased risk of fracture in patients with malignant neoplasms (MN), especially breast cancer (BC), bone health assessment and preventive treatment of osteoporosis (OP) remain partial. Pro-inflammatory cytokines - interleukin(IL)-1β, IL-6, tumour necrosis factor-alpha (TNF-α) - confirm their importance in the development of bone fragility and fractures. The aim of the study: to investigate the influence of systemic inflammatory markers on the severity of osteoporotic changes and to evaluate their association with the estimated 10-year risk of low-energy fractures determined by FRAX in postmenopausal patients with breast cancer. The study included 85 postmenopausal women with MN of various localizations, including 40 patients with BC. All of patients with BC underwent dual-energy X-ray absorptiometry, assessed the 10-year probability of fracture by FRAX, and measured IL-1β, IL-6, and TNF-α by quantitative enzyme-linked immunosorbent assay. The mean time since diagnosis of MN before referral for OP was 3[2.0;4.0] years and differed significantly between groups of individuals with BC (1[1.0;2.0] year) and other MN (4[3.0;5.0] years; p0.001), indicating physicians‘ wariness of osteoporotic complications of BC and patients’ awareness of fracture risks. In patients with MN, OP was diagnosed in 51.2% of cases, and osteopenia - in 37.2%. In the group of BC patients, osteopenia was noted in 16 patients, OP - in 19 patients. Adjuvant chemotherapy was performed in 42.5% of cases in the group of breast cancer patients, and adjuvant hormonal therapy was performed in 87.5% of cases (different regimens of postmenopausal hormone therapy were used). When comparing the cytokine indices in the groups of patients with BC in the presence (47.5%) or absence of OP, it was found: IL-1β was higher in patients with OP both compared to normal and compared to osteopenia (p=0.027 and p=0.029, respectively); IL-6 was higher only in patients with OP compared to normal (p=0.011); TNF-α in OP and osteopenia exceeded those without osteoporotic disorders (p=0.001 and p=0.039, respectively). TNF-α levels correlated with the risk score for large osteoporotic fractures (FRAX:MOF) (rS=0.33, p=0.036) and IL-6 (rS=0.55). A higher 10-year risk of vertebral fractures (p=0.003) was observed in the group of BC patients with ‘high’ ( median) TNF-α levels. In summary, proinflammatory cytokines are actively involved in bone resorption processes, and postmenopausal patients with RA have an increased estimated 10-year risk of low-energy spine fractures in the presence of high TNF-α levels. Patients with BC should be seen by a rheumatologist for OP and low-energy fractures, and active preventive measures should be implemented as early as possible.

  • Relationship between the level of antibodies to the RA-33 antigen and the course of rheumatoid arthritis

    by B.V. Zavodovsky, Yu.R. Akhverdyan, E.V. Papichev, Yu.V. Polyakova, L.E. Sivordova

    Objective: to study the relationship between the serum level of antibodies to the RA-33 antigen and the characteristics of the course of rheumatoid arthritis (RA). Materials and methods. The study included 88 patients with a diagnosis of RA that met the ACR/EULAR criteria, 2010. All observed study participants were women (n=100%), aged from 22 to 81 years (M ± σ, 54.3 ± 12.1 years). Rheumatoid factor was detected in 64 people (72.7%). 59 (67%) study participants were positive for anti-CCP. The duration of RA was 0.5–30 years (M ± σ, 11.2 ± 8.6 years), the degree of activity according to DAS28: 0 degree of activity – 19 (21.6%) patients, 1 degree – 10 (11.6%), 2 degree – 52 (59.1%), 3 degree of activity – 7 (7.7%) patients. Among the observed patients, individuals with III radiological stage of the disease predominated. Statistical processing was performed using the Statistica 12.5 software package for Windows. Results. The level of anti-RA-33 was assessed in a group of RA patients and healthy donors. The level anti-RA-33 was assessed in a group of RA patients and healthy donors. The level normal anti-RA-33 in healthy people, calculated as M±σ, was 10.3±10.2 U/ml (from 0.1 U/ml to 20.5 U/ml). The average level anti-RA-33 in RA patients, calculated as M±σ, was 12.7±31.6 U/ml (from 0 U/ml to 44.3 U/ml). The increase in the level anti-RA-33, compared with donors, is statistically significant (p=0.025) and was observed in 12.5% RA patients. Among 24 patients with RA seronegative by RF, an increase in the level anti-RA-33 was detected in 2 (8.3%) patients, and among 29 patients seronegative by ACCP - also in 2 (6.9%) patients. An increase in the level anti-RA-33 was mainly observed at the initial stages of the disease and with initial radiographic changes. In patients with an increased level anti-RA-33 (more than 20.5 U/ml), pronounced functional disorders were more often detected. Findings. Thus, it can be concluded that antibodies to anti-RA33 can potentially provide additional diagnostic value in RA. Keywords: rheumatoid arthritis, diagnostics of rheumatoid arthritis, antibodies to RA-33, heterogeneous nuclear ribonucleoprotein, HnRPA2B1.

  • Open Access

    Long-term nimesulide use in osteoarthritis: Assessment of requirement, efficacy and safety. Data from the openlabel 3-month observational study NORMA (Nimesulide in Osteoarthritis: vaRious Medical Aspects)

    by A. E. Karateev, E. Yu. Polishchuk, A. M. Lila, Yu. A. Galysheva, L. E. Sivordova, G. V. Lyubieva, Yu. V. Polyakova, Ю. В. Полякова

    Long-term therapy with non-steroidal anti-inflammatory drugs (NSAIDs) may be appropriate in patients with osteoarthritis (OA) who have chronic pain.The aim – to evaluate the efficacy and safety of nimesulide in the 3-month treatment of osteoarthritis.Material and methods. The study group consisted of 282 patients, 79.4% women (age 54.5±8.9 years), with knee OA (50.0%), hip OA (12.4%) and multi-joint OA (37.6%). All patients had comorbidity, including 94.3% arterial hypertension (AH) and 22.7% type 2 diabetes mellitus. All patients had moderate to severe pain (≥4 on a numerical rating scale (NRS 0–10)) for at least 3 months. All patients were prescribed nimesulide 100 mg twice daily. If pain decreased, a reduction in the dose of nimesulide to 100 mg daily or a switch to an on-demand regimen was suggested.Results. After 1 and 3 months of therapy, 82.3% and 49.3% of patients continued to take nimesulide regularly, and 17.4% and 39.7% continued to take it ‘on demand’. 11,0% of patients stopped taking the drug by 3 months, mainly because of pain control or significant pain reduction. In 1 and 3 months all patients showed significant improvement in the severity of the main symptoms of OA. Thus, pain on movement (NRS) decreased from 6.7 to 4.3 and 2.0; WOMAC pain from 11.3 to 7.3 and 3.9; impaired function (NRS) from 5.4 to 3.4 and 1.6; WOMAC function from 38.9 to 25.4 and 14.7 (for all parameters pConclusion. Nimesulide is effective and relatively safe in the long-term treatment of patients with OA and chronic pain.


  • Determination of antinuclear antibodies by immunoblotting to clarify the immunological characteristics of patients with systemic lupus erythematosus and Sjogren's syndrome

    by Yu.R. Akhverdyan, E.V. Papichev, B.V. Zavodovsky, Yu.V. Polyakova, L.E. Sivordova

    Objective: to study the immunological characteristics of patients with systemic lupus erythematosus and Sjogren's syndrome by determining antinuclear antibodies using immunoblotting. Materials and methods. We observed 69 patients whose average age was 38.9 years [23.2-62.9], of which 63 (91.30%) were women and 6 (8.69%) men. BMI was 27.3 kg/m2 [21.8-49.2]. Inclusion criteria: age from 18 to 70 years, presence of a reliable diagnosis. To study the diagnostic value of determining the ANA profile, patients were divided into 3 groups: 1st group – 15 patients with systemic lupus erythematosus (SLE), 2nd – 21 patients with the disease and Sjögren’s syndrome (SS), 3rd (control) group – 33 patients with osteoarthritis. The control group was comparable to the study groups by gender and age. Results. The determination of anti-SS-A in SLE has good quality (area under the ROC curve - 0.66). A cut-off value was determined with 79.6% specificity and 53.3% sensitivity. Anti-RNP/SM, anti-Sm, anti-dsDNA and anti-HI were somewhat less sensitive (30%), with a specificity level of 91% for anti-dsDNA and anti-Sm and 100% for anti-RNP/Sm and anti -HI. The most informative diagnostic tests for the disease and Sjogren's syndrome are anti-Ro-52 recombinant (sensitivity 57.1%, specificity 96%), anti-SS-Anative (sensitivity 52.4%, specificity 86%). The determination of anti-Ro-52 in SS is of good quality, which confirms the value of the area under the ROC curve (>0.7). The optimal cut-off value corresponded to 99.6% specificity and 57.1% sensitivity. Somewhat less sensitive (28.6%) were anti-Sm (specificity - 92%), anti-dsDNA (specificity - 92%) and anti-RIB (specificity 100.0%). Findings. The laboratory tests studied, as a rule, had high specificity, but rather low sensitivity. The most specific tests for diagnosing SLE are antibodies to the antigens RNP/Sm, SS-Anative, antibodies to histones, for SS - anti-SS-Anative, anti-Ro-52 recombinant, anti-RIB. Keywords: systemic lupus erythematosus, Sjögren's syndrome, immunoblotting, antinuclear antibodies.